Investor Relations

We have developed this Investor Relations section to provide our investors (both existing and potential) and our other financial stakeholders with comprehensive, detailed and up to the minute information.

IR-related PDF documents

Syntopix Equity Research Note November 2009
Syntopix One Page Summary April 2009
Proposed Placing of 2,000,756 New Ordinary Shares July 2008
Syntopix Admission Document 2006
Articles of Association 2005

Current share price

View further details on the LSE website here >>

Financial calendar

2009

28 April 2009 - Interim result 2009
7 Jan 2010 - Preliminary results 2009
2 Feb 2010 - Annual General Meeting

2008

24 April 2008 - Interim results 2008
20 October 2008 - Preliminary results 2008
8 December 2008 - Annual General Meeting

2007

19 April 2007 - Interim results 2007
18 October 2007 - Preliminary results 2007
12 December 2007 - Annual General Meeting

Significant shareholders (over 3%)

As at 10 December 2009

Shareholder	No. of Shares	%
IP2IPO Limited (together with Techtran Group Limited)	1,446,832	18.75%
Pershing Nominees Limited	933,197	12.09%
Bank of New York Nominees Limited	847,656	10.98%
The Wellcome Trust Limited	519,168	6.73%
IP Venture Fund Limited	425,977	5.52%
The University of Leeds	390,000	5.05%
Ridings Early Growth Investment Company Limited	322,109	4.17%
Dr Jon Cove	266,180	3.45%
Dr Anne Eady	266,180	3.45%
PH Nominees Limited	233,271	3.02%

Investor relations contact

For all information about Syntopix please contact:

Dr. Stephen P. Jones - Chief Executive Officer
Email: spj@syntopix.com
Tel. +44 (0) 845 125 9204

Syntopix is located at:

Syntopix Group plc
The Institute of Pharmaceutical Innovation
University of Bradford
Bradford
BD7 1DP

Last updated: 13/01/2010

Syntopix

share price

71.00p